奥拉帕利联合阿比特龙治疗BRCA2突变转移性激素敏感性前列腺癌一例
摘要
<正>1病例资料患者男,45岁,因尿频、尿急于2017年4月18日入外院,检测血前列腺特异性抗原(PSA)为606.1ng/mL(正常参考值为1～4ng/mL)。直肠指检:前列腺Ⅲ度大,双侧叶质硬,与直肠可疑粘连。前列腺穿刺病理学检查确诊为前列腺腺癌,Gleason分级4+5。盆腔MRI检查:前列腺外周带异常信号灶,双侧髂血管旁和盆底淋巴结肿大,腰椎、骨盆和双侧股骨转移可能。骨扫描:
引文
[1] PARKER C C,JAMES N D,BRAWLEY C D,et al.Radiotherapy to the primary tumour for newly diagnosed,metastatic prostate cancer (STAMPEDE):a randomised controlled phase 3 trial[J].Lancet,2018,392(10162):2353-2366.
[2] FIZAZI K,TRAN N,FEIN L,et al.Abiraterone plus prednisone in metastatic,castration-sensitive prostate cancer[J].N Engl J Med,2017,377(4):352-360.
[3] JAMES N D,DE BONO J S,SPEARS M R,et al.Abiraterone for prostate cancer not previously treated with hormone therapy[J].N Engl J Med,2017,377(4):338-351.
[4] SWEENEY C J,CHEN Y H,CARDUCCI M,et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J].N Engl J Med,2015,373(8):737-746.
[5] JAMES N D,SYDES M R,CLARKE N W,et al.Addition of docetaxel,zoledronic acid,or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):survival results from an adaptive,multiarm,multistage,platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
[6] PRITCHARD C C,MATEO J,WALSH M F,et al.Inherited DNA-repair gene mutations in men with metastatic prostate Cancer[J].N Engl J Med,2016,375(5):443-453.
[7] 韦煜,吴俊龙,顾伟杰,等.中国前列腺癌患者BRCA1/2及ATM基因的胚系突变研究[J].中国癌症杂志,2018,28(8):584-589.
[8] POMERANTZ M M,SPISáK S,JIA L,et al.The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer[J].Cancer,2017,123(18):3532-3539.
[9] MATEO J,CARREIRA S,SANDHU S,et al.DNA-repair defects and olaparib in metastatic prostate cancer[J].N Engl J Med,2015,373(18):1697-1708.
[10] 中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组.中国前列腺癌患者基因检测专家共识 (2018 年版)[J].中国癌症杂志,2018,28(8):627-633.
[11] CASTRO E,ROMERO-LAORDEN N,DEL POZO A,et al.PROREPAIR-B:a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer[J].J Clin Oncol,2019,37(6):490-503.
[12] ANNALA M,STRUSS W J,WARNER E W,et al.Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer[J].Eur Urol,2017,72(1):34-42.
[13] ANTONARAKIS E S,LU C,LUBER B,et al.Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide[J].Eur Urol,2018,74(2):218-225.
[14] MATEO J,CHENG H H,BELTRAN H,et al.Clinical outcome of prostate cancer patients with germline DNA repair mutations:retrospective analysis from an international study[J].Eur Urol,2018,73(5):687-693.
[2] FIZAZI K,TRAN N,FEIN L,et al.Abiraterone plus prednisone in metastatic,castration-sensitive prostate cancer[J].N Engl J Med,2017,377(4):352-360.
[3] JAMES N D,DE BONO J S,SPEARS M R,et al.Abiraterone for prostate cancer not previously treated with hormone therapy[J].N Engl J Med,2017,377(4):338-351.
[4] SWEENEY C J,CHEN Y H,CARDUCCI M,et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J].N Engl J Med,2015,373(8):737-746.
[5] JAMES N D,SYDES M R,CLARKE N W,et al.Addition of docetaxel,zoledronic acid,or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):survival results from an adaptive,multiarm,multistage,platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
[6] PRITCHARD C C,MATEO J,WALSH M F,et al.Inherited DNA-repair gene mutations in men with metastatic prostate Cancer[J].N Engl J Med,2016,375(5):443-453.
[7] 韦煜,吴俊龙,顾伟杰,等.中国前列腺癌患者BRCA1/2及ATM基因的胚系突变研究[J].中国癌症杂志,2018,28(8):584-589.
[8] POMERANTZ M M,SPISáK S,JIA L,et al.The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer[J].Cancer,2017,123(18):3532-3539.
[9] MATEO J,CARREIRA S,SANDHU S,et al.DNA-repair defects and olaparib in metastatic prostate cancer[J].N Engl J Med,2015,373(18):1697-1708.
[10] 中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组.中国前列腺癌患者基因检测专家共识 (2018 年版)[J].中国癌症杂志,2018,28(8):627-633.
[11] CASTRO E,ROMERO-LAORDEN N,DEL POZO A,et al.PROREPAIR-B:a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer[J].J Clin Oncol,2019,37(6):490-503.
[12] ANNALA M,STRUSS W J,WARNER E W,et al.Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer[J].Eur Urol,2017,72(1):34-42.
[13] ANTONARAKIS E S,LU C,LUBER B,et al.Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide[J].Eur Urol,2018,74(2):218-225.
[14] MATEO J,CHENG H H,BELTRAN H,et al.Clinical outcome of prostate cancer patients with germline DNA repair mutations:retrospective analysis from an international study[J].Eur Urol,2018,73(5):687-693.